The latest evidence now shows that AB23A can upregulate the expression of FXR in the liver and reduce the damage to the liver in pathological conditions such as: nonalcoholic steatohepatitis and cholestatic liver injury [26, 27]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.